Adage Capital Partners’s Avidity Biosciences RNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $43.4M | Sell |
1,527,000
-618,881
| -29% | -$17.6M | 0.07% | 266 |
|
|
2025
Q1 | $63.3M | Sell |
2,145,881
-606,063
| -22% | -$17.9M | 0.12% | 175 |
|
|
2024
Q4 | $80M | Sell |
2,751,944
-327,430
| -11% | -$9.52M | 0.14% | 141 |
|
|
2024
Q3 | $141M | Sell |
3,079,374
-317,608
| -9% | -$14.6M | 0.25% | 75 |
|
|
2024
Q2 | $139M | Buy |
3,396,982
+996,937
| +42% | +$40.7M | 0.26% | 73 |
|
|
2024
Q1 | $61.2M | Buy |
2,400,045
+800,045
| +50% | +$20.4M | 0.12% | 191 |
|
|
2023
Q4 | $14.5M | Buy |
1,600,000
+300,000
| +23% | +$2.72M | 0.03% | 517 |
|
|
2023
Q3 | $8.29M | Buy |
1,300,000
+550,000
| +73% | +$3.51M | 0.02% | 601 |
|
|
2023
Q2 | $8.32M | Buy |
+750,000
| New | +$8.32M | 0.02% | 598 |
|
|
2020
Q3 | – | Sell |
-25,000
| Closed | -$707K | – | 800 |
|
|
2020
Q2 | $707K | Buy |
+25,000
| New | +$707K | ﹤0.01% | 709 |
|